233 related articles for article (PubMed ID: 15268802)
1. [The plasma levels of transforming growth factor beta1 and the protein expressions of alpha-SMA, urokinase plasminogen activator and plasminogen activator inhibitor-1 in liver of patients with different grades of hepatic fibrosis].
Wu XR; Lv MH; Wang Q; Shi SS; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):400-2. PubMed ID: 15268802
[TBL] [Abstract][Full Text] [Related]
2. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
3. [The plasma levels of urokinase plasminogen activator and plasminogen activator inhibitor-1 and the protein expressions of alpha-SMA and MMP-1 and TIMP-1 in patients with different grades of liver fibrosis].
Bai K; Guo CJ
Zhonghua Gan Zang Bing Za Zhi; 2006 Jun; 14(6):459-61. PubMed ID: 16792874
[No Abstract] [Full Text] [Related]
4. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms.
Lindholt JS; Jørgensen B; Shi GP; Henneberg EW
Eur J Vasc Endovasc Surg; 2003 Jun; 25(6):546-51. PubMed ID: 12787697
[TBL] [Abstract][Full Text] [Related]
5. [The relationship between TGFbeta1 and TIMP-1 and its effects on the diagnosis of hepatic fibrosis].
Zhang LF; Tian XX; Wang CF
Zhonghua Gan Zang Bing Za Zhi; 2007 Apr; 15(4):258-60. PubMed ID: 17456311
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
7. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
8. [The relationship between hepatic expression, serum level of TGFbeta1 and the hepatic fibrosis in patients with viral hepatitis].
Li BS; Yan WZ; Liu JX; Zhen Z; Kong L; Liu F
Zhonghua Gan Zang Bing Za Zhi; 2004 May; 12(5):271-3. PubMed ID: 15161500
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of plasminogen activator inhibitor-1 expression by siRNA in rat hepatic stellate cells.
Hu PF; Zhu YW; Zhong W; Chen YX; Lin Y; Zhang X; Yin C; Yue HY; Xie WF
J Gastroenterol Hepatol; 2008 Dec; 23(12):1917-25. PubMed ID: 18761555
[TBL] [Abstract][Full Text] [Related]
10. The plasminogen-activating system in hepatic stellate cells.
Leyland H; Gentry J; Arthur MJ; Benyon RC
Hepatology; 1996 Nov; 24(5):1172-8. PubMed ID: 8903394
[TBL] [Abstract][Full Text] [Related]
11. [Expression and plasma activity of plasminogen activator inhibitor-1 infibrotic liver tissues].
Li Q; Qin C; Lao P
Zhonghua Gan Zang Bing Za Zhi; 2000 Aug; 8(4):209-11. PubMed ID: 10951619
[TBL] [Abstract][Full Text] [Related]
12. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
13. Transplantation of urokinase-type plasminogen activator gene-modified bone marrow-derived liver stem cells reduces liver fibrosis in rats.
Sun C; Li DG; Chen YW; Chen YW; Wang BC; Sun QL; Lu HM
J Gene Med; 2008 Aug; 10(8):855-66. PubMed ID: 18481824
[TBL] [Abstract][Full Text] [Related]
14. [Effect of polymorphism of transforming growth factor beta1 gene on HBV-induced liver cirrhosis].
Yang ZX; Wang H; Gao CF; Xu LL; Zhao WJ
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(15):1021-6. PubMed ID: 16029542
[TBL] [Abstract][Full Text] [Related]
15. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
[TBL] [Abstract][Full Text] [Related]
16. Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice.
Xu W; Wang LW; Shi JZ; Gong ZJ
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):300-8. PubMed ID: 19502172
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
[TBL] [Abstract][Full Text] [Related]
18. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
19. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
20. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
